4 ms·
See a rather scathing rebuttal here: http://blogs.sciencemag.org/pipeline/archives/2017/01/11/12110 http://blogs.sciencemag.org/pipeline/archives/2017/01/11/121
by hprotagonist 10y ago
See a rather scathing rebuttal here: http://blogs.sciencemag.org/pipeline/archives/2017/01/11/12110 http://blogs.sciencemag.org/pipeline/archives/2017/01/11/121...
>You would never know, to read a lot of Ramaswamy’s press coverage (here’s a recent profile from TechCrunch) that the Axovant drug works through a mechanism that has failed twice in Alzheimer’s clinical trials so far.
>You wouldn’t know from such articles, though, that there have been (and are) other companies which have been formed around the idea of taking pharma cast-offs and getting them through the clinic (larger companies already try to monetize what they can in their portfolio by partnering or outlicensing, of course). The Medicines Company is one such dealmaker, acquiring and partnering late-stage compounds and trying to get them approved. Outside of the for-profit business model, there are a number of initiatives trying to repurpose or revive older compounds for new diseases.No one so far has been able to take over the world doing this. There are not, unfortunately, many big piles of such candidates sitting around. Most of the shelved compounds were shelved because (a) they did not work, and/or (b) they showed toxicity. You’re going to have to figure a way around those problems before you go back into humans, and that’s not easy. There are a few drugs that have been dropped for business reasons, or were lost or mishandled during a merger or the like, but I don’t think that there are enough of those to make a Ramaswamy drug empire.
- andrewtbham 10y agoIf you're confident this is true... why not short the stock? if correct, you could make a lot of money.
- deepnotderp 10y agoIs it public?
- SpeakMouthWords 10y agoFrom the article: >It was the biggest biotech IPO ever in the U.S., raising $360 million. It has largely held up, too. Axovant’s shares, which opened at $15, currently trade around $13.25. and further down: > When Axovant went public, a columnist at FierceBiotech warned that it should “scare the hell” out of investors
- in_cahoots 10y ago"The market can remain irrational longer than you can remain solvent." The quote itself may be apocryphal, but the meaning is certainly true.
- danieltillett 10y agoNever short based on the rationality of the market. Plenty of investors have been right and ended up totally broke. On a personal note the worst investment I ever made was a short position where I was right, but six months too early.
- jimlawruk 10y agoReminds me of Michael Burry and others in The Big Short, who shorted the housing market, but had to wait a long time for the market adjust.
- adventured 10y agoNever short a stock, use puts. You define your maximum potential loss ahead of time. By doing so you can entirely remove the solvency factor in question. Then it becomes a matter of giving yourself enough time on the puts to be right (assuming your core premise is correct).
- sfifs 10y agoYou're assuming puts of sufficient duration would be available and liquid.
- aub3bhat 10y agoExactly Derek Lowe is a classic academic without any skin in the game. Rather than appreciating risk taking he displays the sour grapes mentality. He is always welcome to short the stock. But then this kind skepticism against anyone else becoming rich sells very well in academic circles.
- hprotagonist 10y agoyou do realize he works for a pharma company, right? The last time he was an academic was when he was a postdoc. In the mid-80s. he's discussed his stock positions a few times; the takeaway is along the lines of "i don't have any holdings that could be construed as bias as regards where this blog is hosted; otherwise it's my own business" if i remember right.
- aub3bhat 10y agoThats even worse. Derek Lowe is playing the classic no one ever went broke being skeptic move. These blogs are written to assuage egos of underpaid academics, who can't stand wealth creation nor understand risk taking. In fact if he really belives it then he must put money behind his words. And then donate earnings to whatever cause he believes in. Untill then its just sour grapes.
- dikdik 10y agoThe big way they are figuring out how to repurpose old compounds that fell out of the pipeline is by using biomarkers. We are now much more equipt at finding biomarkers, generally through gene sequencing. Drugs that failed, often failed because they were applied to an entire population of a disease (ie multiple sclerosis). Now, we can subset the MS population by different biomarkers and test just that small subset for efficacy. While testing anyone that happens to have MS would show a massive failure rate, testing 5% of the population that has specific biomarkers, we may be able to show a huge increase in efficacy and thus the drug would be approved for MS patients that fit the exact bio marker profile.
- akiselev 10y agoThere is another consequence: the FDA may allow you to classify the compound as an orphan drug based on a much smaller market than the entire disease pool. This greatly reduces the burden of getting a drug approved because orphan drugs have too few patients to justify the expense of the usual approval process and the FDA gives them special treatment for humanitarian reasons and to promote a wider field of research than just the drugs with large profit potential.
- hprotagonist 10y agobiomarker validation is just as annoying as drug testing, so you're just punting the problem one node down. it's hard work: http://blogs.sciencemag.org/pipeline/archives/2013/12/04/cancer_cell_line_assays_you_wont_like_hearing_this http://blogs.sciencemag.org/pipeline/archives/2013/12/04/can... nominal biomarkers can be wholly spurious: http://blogs.sciencemag.org/pipeline/archives/2012/04/10/biomarker_caution http://blogs.sciencemag.org/pipeline/archives/2012/04/10/bio... biomarkers that we believe to be proxies for disease conditions (like LDL) can be targeted to no effect: http://blogs.sciencemag.org/pipeline/archives/2016/12/14/simple-right http://blogs.sciencemag.org/pipeline/archives/2016/12/14/sim... etc.
- sammydavis 10y agoI didn't think the article was so scathing. It was very inside baseball from my software engineer basis, hard to understand what he was getting at. On the other hand, the article about axovant (the $5mil cast off drug they spun into a 1.x billion dollar company and it apparently doesn't work), that article was persuasive that I should short this. How come the axovant stock hasn't collapsed.